Enzymatic preparation of κ-carrageenan oligosaccharides and their anti-angiogenic activity

被引:77
|
作者
Yao, Ziang [1 ]
Wu, Haige [1 ,2 ]
Zhang, Shengxia [1 ]
Du, Yuguang [2 ]
机构
[1] Dalian Univ, Sch Life Sci & Technol, Dalian 116622, Peoples R China
[2] Chinese Acad Sci, Dalian Inst Chem Phys, Dalian 116023, Peoples R China
基金
中国国家自然科学基金;
关键词
kappa-Carrageenan oligosaccharides; Anti-tumor; Anti-angiogenesis; CD; 105; IN-VITRO; INHIBITS ANGIOGENESIS; THERAPY; GROWTH; TUMOR; GIGARTINALES; ANTITUMOR; FRACTION; TARGETS; CANCER;
D O I
10.1016/j.carbpol.2013.09.055
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The mixture of kappa-neocarrabiose-sulfate, kappa-neocarrahexaose-sulfate and kappa-neocarraoctaose-sulfate were prepared from kappa-carrageenan with enzyme. The anti-tumor and anti-angiogenic activity of obtained kappa-carrageenan oligosaccharides (KOS), were explored. The results showed that KOS could inhibit the proliferation, migration and tube formation of ECV304 cells, and could inhibit the growth of new vessels in CAM model. KOS displayed strong anti-tumor activity in both S180 and MCF-7 xenograft models. Only human CD105 was detected in MCF-7 xenograft tumor, moreover KOS could decrease the growing of new blood vessels derived from tumor cell. Real-time PCR results showed that KOS could suppress the mRNA expression of human VEGF, bFGF, bFGFR and CD105 in MCF-7 xenograft tumor. All these results indicated that KOS has anti-tumor and anti-angiogenic activity in vivo and in vitro. Especially K has the potency to inhibit the differentiation of tumor cell to blood vessel endothelial cell. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:359 / 367
页数:9
相关论文
共 50 条
  • [1] Oligosaccharides as anti-angiogenic agents
    Cole, Claire Louise
    Jayson, Gordon C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (03) : 351 - 362
  • [2] The development of oligosaccharides as anti-angiogenic agents
    Jayson, GC
    Pye, D
    McGown, AT
    Gallagher, JT
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S62 - S62
  • [3] The development of anti-angiogenic heparan sulfate oligosaccharides
    Jayson, Gordon C.
    Miller, Gavin J.
    Hansen, Steen U.
    Barath, Marek
    Gardiner, John M.
    Avizienyte, Egle
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2014, 42 : 1596 - 1600
  • [4] Anti-Angiogenic Property of Free Human Oligosaccharides
    Bae, Boram
    Kim, Haeun
    Park, Hyerin
    Koh, Young Jun
    Bae, Sung-Jin
    Ha, Ki-Tae
    BIOMOLECULES, 2021, 11 (06)
  • [5] Anti-angiogenic activity of tocotrienol
    Inokuchi, H
    Hirokane, H
    Tsuzuki, T
    Nakagawa, K
    Igarashi, M
    Miyazawa, T
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2003, 67 (07) : 1623 - 1627
  • [6] ANTI-ANGIOGENIC ACTIVITY OF SURAMIN
    COLLINS, D
    GAGLIARDI, A
    FASEB JOURNAL, 1992, 6 (05): : A1600 - A1600
  • [7] Anti-angiogenic activity of azathioprine
    Bisneto, Abel Vieira de Melo
    Fernandes, Amanda Silva
    Sa, Vivianne de Souza Velozo
    Veras, Jefferson Hollanda
    Soares, Estefane Thaine Sodre
    Santos, Aline Ferreira da Silva
    Cardoso, Clever Gomes
    Silveira-Lacerda, Elisangela de Paula
    Carneiro, Cristiene Costa
    Chen-Chen, Lee
    MICROVASCULAR RESEARCH, 2021, 138
  • [8] Anti-angiogenic activity of salvicine
    Zhang, Yanli
    Wang, Lei
    Chen, Yajuan
    Qing, Chen
    PHARMACEUTICAL BIOLOGY, 2013, 51 (08) : 1061 - 1065
  • [9] ANTI-ANGIOGENIC ACTIVITY OF TRITERPENE ACIDS
    SHON, KH
    LEE, HY
    CHUNG, HY
    YOUNG, HS
    YI, SY
    KIM, KW
    CANCER LETTERS, 1995, 94 (02) : 213 - 218
  • [10] Preparation and in vivo antitumor activity of κ-carrageenan oligosaccharides
    Hu, Xiaoke
    Jiang, Xiaolu
    Aubree, Eric
    Boulenguer, Patrick
    Critchley, Alan T.
    PHARMACEUTICAL BIOLOGY, 2006, 44 (09) : 646 - 650